My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

46.01 -1.02 (-2.17%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

40 41 Next >

Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis ↗

September 29, 2022

Via Benzinga

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test ↗

September 23, 2022

Though successful in early testing, it wasn't enough to win a Phase 3 study.

Via Investor's Business Daily

NASDAQ:SNY Investor Alert: Investigation over Potential Wrongdoing at Sanofi ↗

September 20, 2022

San Diego, CA -- (SBWIRE) -- 09/20/2022 -- An investigation on behalf of investors in shares of Sanofi (NASDAQ:SNY) was announced over potential breaches of fiduciary duties by certain directors at...

Via SBWire

Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer ↗

September 20, 2022

Via Benzinga

Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger ↗

September 19, 2022

Via Benzinga

AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing ↗

September 16, 2022

Via Benzinga

Sanofi's Rare Disease Drug Xenpozyme Scores FDA Approval ↗

September 01, 2022

Via Benzinga

Sanofi's Hemophilia Candidate Goes Under Priority FDA Review ↗

August 30, 2022

Via Benzinga

TG Therapeutics Touts Encouraging Data From Multiple Sclerosis Candidate ↗

August 25, 2022

Via Benzinga

ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients ↗

September 14, 2022

Via Benzinga

Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease ↗

September 08, 2022

Via Benzinga

Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report ↗

September 06, 2022

Via Benzinga

Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids ↗

September 06, 2022

Via Benzinga

Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash... ↗

September 01, 2022

Wall Street Journal

Via Benzinga

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report ↗

August 30, 2022

Via Benzinga

Upstart Digital Health Company, DarioHealth, Announces Significant Contract with National Health Plan Provider, Giving Millions Access to Mental Health Resources ↗

August 24, 2022

DarioHealth Corp. (NASDAQ: DRIO) recently announced

Via Benzinga

MarketBeat: Week in Review 8/15 - 8/19

August 20, 2022

The economic reports continue to signal volatility. You can count on MarketBeat analysts to bring you the stocks and stories that are driving the market.

Via MarketBeat

Topics Economy Workforce

Stocks That Hit 52-Week Lows On Thursday ↗

August 25, 2022

On Thursday, 63 companies set new 52-week lows.

Via Benzinga

Is Sanofi A Buy, Despite Recent Stumbles?

August 19, 2022

Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.

Via MarketBeat

Topics Intellectual Property

Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated

August 18, 2022

By Mark Gilman -- Benzinga

Via News Direct

Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated

August 18, 2022

Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds...

Via TheNewswire.com

Sanofi's Breast Cancer Drug Fallout 'Creates Buying Opportunity' For This Stock ↗

August 18, 2022

According to Oppenheimer analyst, the fallout of Sanofi SA's (NASDAQ: SNY) amcenestrant creates a buying opportunity for Arvinas Inc (NASDAQ: ARVN)

Via Benzinga

Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated ↗

August 18, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

August 18, 2022

During Thursday's trading, 62 companies set new 52-week lows.

Via Benzinga

Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial ↗

August 17, 2022

Via Benzinga

Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday ↗

August 17, 2022

Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split.

Via Benzinga

This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday ↗

August 18, 2022

Gainers

Via Benzinga

Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session ↗

August 17, 2022

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus...

Via Benzinga

Sanofi's Run Of Bad Luck Continues As Pharma Giant Tosses Out A Cancer Drug ↗

August 17, 2022

Shares extended deep losses following a Zantac-inspired downturn last week.

Via Investor's Business Daily

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.